Your browser doesn't support javascript.
loading
Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis.
Pastushenko, Ievgenia; Mauri, Federico; Song, Yura; de Cock, Florian; Meeusen, Bob; Swedlund, Benjamin; Impens, Francis; Van Haver, Delphi; Opitz, Matthieu; Thery, Manuel; Bareche, Yacine; Lapouge, Gaelle; Vermeersch, Marjorie; Van Eycke, Yves-Rémi; Balsat, Cédric; Decaestecker, Christine; Sokolow, Youri; Hassid, Sergio; Perez-Bustillo, Alicia; Agreda-Moreno, Beatriz; Rios-Buceta, Luis; Jaen, Pedro; Redondo, Pedro; Sieira-Gil, Ramon; Millan-Cayetano, Jose F; Sanmatrtin, Onofre; D'Haene, Nicky; Moers, Virginie; Rozzi, Milena; Blondeau, Jeremy; Lemaire, Sophie; Scozzaro, Samuel; Janssens, Veerle; De Troya, Magdalena; Dubois, Christine; Pérez-Morga, David; Salmon, Isabelle; Sotiriou, Christos; Helmbacher, Francoise; Blanpain, Cédric.
Afiliação
  • Pastushenko I; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Mauri F; Dermatology Department, Cliniques de l'Europe, Brussels, Belgium.
  • Song Y; Dermatology Department, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • de Cock F; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Meeusen B; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Swedlund B; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Impens F; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Van Haver D; Leuven Cancer Institute (LKI), Leuven, Belgium.
  • Opitz M; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Thery M; VIB Center for Medical Biotechnology, Ghent, Belgium.
  • Bareche Y; VIB Proteomics Core, Ghent, Belgium.
  • Lapouge G; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Vermeersch M; VIB Center for Medical Biotechnology, Ghent, Belgium.
  • Van Eycke YR; VIB Proteomics Core, Ghent, Belgium.
  • Balsat C; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
  • Decaestecker C; Alvéole, Paris, France.
  • Sokolow Y; CytoMorpho Lab, UMR976 HIPI, CEA, INSERM, Université de Paris, Paris, France.
  • Hassid S; CytoMorpho Lab, UMR5168 LPCV, CEA, CNRS, Université Grenoble-Alpes, Grenoble, France.
  • Perez-Bustillo A; Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Agreda-Moreno B; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Rios-Buceta L; Center for Microscopy and Molecular Imaging (CMMI), Université Libre de Bruxelles (ULB), Charleroi, Belgium.
  • Jaen P; DIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Charleroi, Belgium.
  • Redondo P; Laboratory of Image Synthesis and Analysis, Ecole Polytechnique de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Sieira-Gil R; DIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Charleroi, Belgium.
  • Millan-Cayetano JF; DIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Charleroi, Belgium.
  • Sanmatrtin O; Laboratory of Image Synthesis and Analysis, Ecole Polytechnique de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • D'Haene N; Department of Thoracic Surgery, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Moers V; Department of Otolaryngology - Head and Neck Surgery, Erasme University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Rozzi M; Department of Dermatology, Complejo Asistencial Universitario de León, León, Spain.
  • Blondeau J; Department of Otolaryngology - Head and Neck Surgery, Hospital Clinico 'Lozano Blesa', Zaragoza, Spain.
  • Lemaire S; Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
  • Scozzaro S; University of Alcalá, Madrid, Spain.
  • Janssens V; Instituto Ramón y Cajal de Investigación Sanitaria (IRyCIS), Madrid, Spain.
  • De Troya M; Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
  • Dubois C; University of Alcalá, Madrid, Spain.
  • Pérez-Morga D; Instituto Ramón y Cajal de Investigación Sanitaria (IRyCIS), Madrid, Spain.
  • Salmon I; Department of Dermatology, Clinica Universidad de Navarra, Navarra, Spain.
  • Sotiriou C; Department of Maxillofacial Surgery, Head and Neck Surgery, Hospital Clínic, Barcelona, Spain.
  • Helmbacher F; Department of Dermatology, Hospital Costa del Sol, Marbella, Spain.
  • Blanpain C; Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
Nature ; 589(7842): 448-455, 2021 01.
Article em En | MEDLINE | ID: mdl-33328637
ABSTRACT
FAT1, which encodes a protocadherin, is one of the most frequently mutated genes in human cancers1-5. However, the role and the molecular mechanisms by which FAT1 mutations control tumour initiation and progression are poorly understood. Here, using mouse models of skin squamous cell carcinoma and lung tumours, we found that deletion of Fat1 accelerates tumour initiation and malignant progression and promotes a hybrid epithelial-to-mesenchymal transition (EMT) phenotype. We also found this hybrid EMT state in FAT1-mutated human squamous cell carcinomas. Skin squamous cell carcinomas in which Fat1 was deleted presented increased tumour stemness and spontaneous metastasis. We performed transcriptional and chromatin profiling combined with proteomic analyses and mechanistic studies, which revealed that loss of function of FAT1 activates a CAMK2-CD44-SRC axis that promotes YAP1 nuclear translocation and ZEB1 expression that stimulates the mesenchymal state. This loss of function also inactivates EZH2, promoting SOX2 expression, which sustains the epithelial state. Our comprehensive analysis identified drug resistance and vulnerabilities in FAT1-deficient tumours, which have important implications for cancer therapy. Our studies reveal that, in mouse and human squamous cell carcinoma, loss of function of FAT1 promotes tumour initiation, progression, invasiveness, stemness and metastasis through the induction of a hybrid EMT state.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Caderinas / Deleção de Genes / Transição Epitelial-Mesenquimal / Metástase Neoplásica / Neoplasias Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Caderinas / Deleção de Genes / Transição Epitelial-Mesenquimal / Metástase Neoplásica / Neoplasias Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article